Data from the phase 2 study (EQUATOR-trial) shows that filgotinib is efficacious and safe in patients with psoriatic arthritis (PsA) . “The selected Janus kinase (JAK)1 inhibitor improves multiple domains of PsA. No new safety data were obtained. This drug will be explored further in future PsA trials,” concluded Prof. Philip Mease (Swedish Medical Center and University of Washington, Seattle, USA) .
Filgotinib is an oral, selective JAK1 inhibitor in development for the treatment of several inflammatory diseases . Prof. Mease et al. aimed to evaluate the onset and maintenance of response to filgotinib vs placebo in the EQUATOR trial by evaluating patient-level response over time. “What we are doing with this analysis is looking in a novel way at treatment response,” he said. The primary objective was to evaluate the time to first response on patient-level and the individual duration of response, compared with placebo. The secondary objectives were...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« Emapalumab in Patients with Macrophage Activation Syndrome Next Article
Clinical Effectiveness of Fenebrutinib in RA Patients with Methotrexate or TNFI Failure »
Table of Contents: EULAR 2019
Osteoarthritis and Osteoporosis
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.